Mouse Advanced Glycosylation End Product Specific Receptor (AGER) ELISA Kit
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Mouse Advanced Glycosylation End Product Specific Receptor (AGER) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Mouse Advanced Glycosylation End Product Specific Receptor concentrations in serum, plasma and other biological fluids.
Documents del producto
Product specifications
| Category | ELISA Kits |
| Immunogen Target | Advanced Glycosylation End Product Specific Receptor (AGER) |
| Reactivity | Mouse |
| Detection Method | Colorimetric |
| Assay Data | Quantitative |
| Assay Type | Sandwich |
| Test Range | 31.25 pg/ml - 2000 pg/ml |
| Sensitivity | 18.75 pg/ml |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Size 1 | 96 tests |
| Size 2 | 5 × 96 tests |
| Size 3 | 10 × 96 tests |
| Form | Lyophilized |
| Tested Applications | ELISA |
| Sample Type | Serum, plasma and other biological fluids. |
| Availability | Shipped within 5-7 working days. The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request. |
| Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
| Dry Ice | No |
| Alias | RAGE,SCARJ1,sRAGE |
| Background | Elisa kits for AGER |
| Status | RUO |
| Note | Validity: The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request. This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |
Descripción
AGER, also known as RAGE (Receptor for Advanced Glycation End Products), is a transmembrane receptor belonging to the immunoglobulin superfamily that binds to AGEs and other ligands such as S100 proteins, HMGB1, and amyloid-β. AGER is widely expressed, particularly in the endothelium, lungs, brain, and immune cells, and plays a critical role in inflammatory and oxidative stress signaling. Binding of AGEs to AGER activates downstream pathways, including NF-κB, MAPK, and JAK/STAT, leading to the production of pro-inflammatory cytokines and reactive oxygen species. Overexpression or chronic activation of AGER is associated with diseases such as diabetes complications, atherosclerosis, Alzheimer’s disease, and cancer, where it exacerbates inflammation and tissue damage. AGER is a promising therapeutic target for reducing AGE-mediated pathologies and modulating immune and metabolic dysfunction.
Related Products
Mouse AGER(Advanced Glycosylation End Product Specific Receptor) ELISA Kit
Ver Producto
anti- AGER antibody
Mediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling(By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide(ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase(MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.
Ver Producto
anti- AGER antibody
Mediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling(By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide(ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase(MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.
Ver Producto